Physician profile
Sa Dean Drooby
NPI 1598747354
$4,189.07
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,596 · 2020: $1,011 · 2021: $583.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.30 | 2019-2021 | |
| Amgen INC. | $687.93 | 2019-2021 | |
| Amarin Pharma, INC. | $433.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $373.24 | 2019-2020 | |
| Novo Nordisk INC | $356.40 | 2020-2021 | |
| Lilly USA, LLC | $308.21 | 2019 | |
| Allergan, INC. | $286.33 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $125.11 | 2019 | |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Corcept Therapeutics | $124.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $123.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $121.01 | 2019 | |
| Astellas Pharma US INC | $111.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $105.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $102.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sa Drooby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.